Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;71(5):672-83.
doi: 10.1111/j.1365-2125.2010.03703.x.

Skin manifestations of drug allergy

Affiliations
Review

Skin manifestations of drug allergy

Michael R Ardern-Jones et al. Br J Clin Pharmacol. 2011 May.

Abstract

Cutaneous adverse drug reactions range from mild to severe and from those localized only to skin to those associated with systemic disease. It is important to distinguish features of cutaneous drug reactions which help classify the underlying mechanism and likely prognosis as both of these influence management decisions, some of which necessarily have to be taken rapidly. Severe cutaneous reactions are generally T cell-mediated, yet this immunological process is frequently poorly understood and principles for identification of the culprit drug are different to those of IgE mediated allergic reactions. Furthermore, intervention in severe skin manifestations of drug allergy is frequently necessary. However, a substantial literature reports on success or otherwise of glucocorticoids, cyclophsphamide, ciclosporin, intravenous immunoglobulin and anti-tumour necrosis factor therapy for the treatment of toxic epidermal necrolysis without clear consensus. As well as reviewing the recommended supportive measures and evidence base for interventions, this review aims to provide a mechanistic overview relating to a proposed clinical classification to assist the assessment and management of these complex patients.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Clinical photographs depicting classic examples of four similar cutaneous drug eruption patterns. Of note, the plaques of urticarial eruptions (A) have pale centres in contrast to the uniform colour in drug-induced exanthemata (B) and drug reaction with eosinophilia and systemic symptoms (DRESS) (C) and the dark centre (target) in erythema multiforme (D)
Figure 3
Figure 3
A clinical image of toxic epidermal necrolyisis (TEN) demonstrating widespread patchy eryhthema with confluence and darkening at sites of epidermal detachment (blistering)
Figure 1
Figure 1
Careful documentation, with detailed dating of when drugs were started and stopped reveals the timelines which, in conjunction with knowledge of individual reported frequencies of allergy, helps to rank the drugs in order of suspicion. In a severe drug reaction such as toxic epidermal necrolysis, although this format is still very useful to identify a causative drug, it is preferable to recommend cessation of all medications. Time spent accurately drawing out this information at the first clinical encounter is considerably more effective than attempting to do this retrospectively when the condition has resolved. Horizontal arrows represent period of ingestion of listed drug. Arrow tip represents last day of ingestion. Vertical arrow represents a medication switch. Vertical dotted line represents the onset of the rash. It is important to include annotation of the day the chart is documented (Today)

Similar articles

  • Annular drug eruptions.
    Wu WH, Chu CY. Wu WH, et al. Clin Dermatol. 2022 Sep-Oct;40(5):450-465. doi: 10.1016/j.clindermatol.2021.12.008. Epub 2021 Dec 31. Clin Dermatol. 2022. PMID: 34979270
  • [DRUG INDUCED EXANTHEMA AND SEVERE CUTANEOUS DRUG REACTIONS].
    Bensaïd B, Valeyrie-Allanore L, Lebrun-Vignes B, Nicolas JF. Bensaïd B, et al. Rev Prat. 2015 Sep;65(7):981-5. Rev Prat. 2015. PMID: 26619740 French.
  • Exanthems and drug reactions.
    Rawlin M. Rawlin M. Aust Fam Physician. 2011 Jul;40(7):486-9. Aust Fam Physician. 2011. PMID: 21743852 Review.
  • Adverse drug reactions and organ damage: The skin.
    Marzano AV, Borghi A, Cugno M. Marzano AV, et al. Eur J Intern Med. 2016 Mar;28:17-24. doi: 10.1016/j.ejim.2015.11.017. Epub 2015 Dec 7. Eur J Intern Med. 2016. PMID: 26674736 Review.
  • [Adverse cutaneous reactions to drugs].
    Suástegui-Rodríguez I, Campos-Jiménez KI, Domínguez-Cherit J, Méndez-Flores S. Suástegui-Rodríguez I, et al. Rev Med Inst Mex Seguro Soc. 2018 Jan-Feb;56(1):64-70. Rev Med Inst Mex Seguro Soc. 2018. PMID: 29368897 Review. Spanish.

Cited by

References

    1. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358–63. - PubMed
    1. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52:388–93. - PubMed
    1. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018–22. - PubMed
    1. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol. 1992;34:377–95. - PMC - PubMed
    1. Merk HF, Hertl M. Immunologic mechanisms of cutaneous drug reactions. Semin Cutan Med Surg. 1996;15:228–35. - PubMed

MeSH terms